WHO and MPP announce the first transparent, global, non-exclusive licence for a COVID-19 technology
Pfizer and The Medicines Patent Pool (MPP) Sign Licensing Agreement for COVID-19 Oral Antiviral Treatment Candidate to Expand Access in Low- and Middle-Income Countries
The Medicines Patent Pool (MPP) and MSD enter into licence agreement for molnupiravir, an investigational oral antiviral COVID-19 medicine, to increase broad access in low- and middle- income countries
The Medicines Patent Pool (MPP) is a United Nations-backed public health organisation working to increase access to, and facilitate the development of, life-saving medicines for low- and middle-income countries. Through its innovative business model, MPP partners with civil society, governments, international organisations, industry, patient groups, and other stakeholders, to prioritise and license needed medicines and pool intellectual property to encourage generic manufacture and the development of new formulations.
To date, MPP has signed agreements with twelve patent holders for thirteen HIV antiretrovirals, one HIV technology platform, three hepatitis C direct-acting antivirals, a tuberculosis treatment, a long-acting technology, two experimental oral antiviral treatments for COVID-19 and a COVID-19 serological antibody diagnostic test. In 2020, MPP’s mandate was temporarily expanded to include COVID-19 treatments. In 2021 it was expanded further to include the licensing of technology with an initial focus on COVID-19 vaccines and pandemic preparedness.
MPP was founded by Unitaid, which continues to be MPP’s main funder. MPP’s work on access to essential medicines is also funded by the Swiss Agency for Development and Cooperation (SDC). MPP’s activities in COVID-19 are undertaken with the financial support of the Japanese Government and SDC.
"The Medicines Patent Pool was established as a landmark initiative to expand access to treatments for priority diseases. Over the last decade, MPP has become a strong partner in global health, working to facilitate access to HIV and hepatitis C medicines in low- and middle-income countries through voluntary licensing and patent pooling. With its impressive track record, MPP has a critical role to play in making affordable versions of patented essential medicines and technologies available to those who need it the most, including for COVID-19."Dr Tedros Adhanom Ghebreyesus, Director-General, World Health Organization
"The creation fo the Medicines Patent Pool by Unitaid ten years ago enabled the production of generics that treat tens of millions of people around the world. This led to important successes such as an annual treatment for HIV/AIDS for less than USD 70 in Africa, instead of USD 10,000 in Europe. Today, maybe more than ever, we need MPP’s model to help pharmaceutical companies license their rights on a voluntary basis and continue to save lives."Marisol Touraine, Chair of the Executive Board of Unitaid
"As the Medicines Patent Pool celebrates its ten-year anniversary, we are proud to support MPP’s effort to speed up access to essential medicines in low- and middle-income countries. MPP’s voluntary licence mechanism is very much needed, especially in times of the COVID-19 pandemic, as it promotes a collaborative vision of ensuring rapid access of quality-assured affordable essential medicines to people living in low- and middle-income countries while acknowledging the need to fund innovation."Alexander Schulze, Head of the Division Global Programme Health, Federal Department of Foreign Affairs, Swiss Agency for Development and Cooperation
MPP in Numbers
patent holders with MPP signed agreements
generic manufactures and product developers have sublicenses from MPP
For Everyone Everywhere
Discover where we helped and what we have achieved
Patent and licensing status: last updated on 11 May 2021. Disclaimer | Product availability data from MPP sublicensees: last updated in October 2021 (data as of 30 June 2021) | Note: Sales may occur in countries in the absence of registration via procurement channels, registration waivers and/or exemptions
How access to antiretrovirals is building the future
El acuerdo de licencia #CSIC-@MedsPatentPool (MPP) firmado bajo auspicio de la C-TAP de la @WHO es: ✅La primera licencia mundial no exclusiva de una herramienta covid ✅La primera licencia de tecnología de diagnóstico firmada por la MPP ✅La primera licencia incluida en la C-TAP https://t.co/IQrtiiS4pw
Tedros Adhanom Ghebreyesus @DrTedros
Today, @WHO & @MedsPatentPool announce the first transparent, global, non-exclusive licence for a #COVID19 test, developed by @CSIC from Spain 🇪🇸. We call on all developers of COVID-19 treatment & diagnostics to follow this example & expand access to these life-saving tools https://t.co/kAye6wgr89 https://t.co/vG41PzSWTa
W/ the aim of facilitating rapid supply of @CSIC’s #COVID19 serological test worldwide, the @CSIC-@MedsPatentPool licence👇 ✅covers patents+biological material for manufacture ✅includes know-how ✅is royalty-free for #LMICs 🗞️https://t.co/BtSXmDU1O0 #PublicHealth #HealthForAll https://t.co/S8BA1vwOsE
🔎 The @CSIC-@MedsPatentPool licence agreement signed under the leadership of @WHO's C-TAP is: ✅1st global, non-exclusive licence for a #COVID19 health tool ✅1st #Diagnostic Tech licence signed by MPP ✅1st licence included in @WHO’s C-TAP 👉 https://t.co/BtSXmDU1O0 https://t.co/e9hys7Wtf5
World Health Organization (WHO) @WHO
WHO & @MedsPatentPool announce the first transparent, global, non-exclusive licence for a #COVID19 technology, after finalizing a licensing agreement with @CSIC for a COVID-19 serological antibody technology. 👉 https://t.co/MWRbQNEjkw https://t.co/q6Zj2p0OYi
El CSIC firma un acuerdo de licencia mundial con @MedsPatentPool para que sus test de anticuerpos de covid-19 lleguen a los países en desarrollo. Se enmarca en la iniciativa de Acceso Mancomunado a la Tecnología contra la covid-19 (C-TAP) de la OMS @WHO ➡️https://t.co/nnpo0UqHmY https://t.co/PvmK8FeEFf